BioPoly® Patent Issues
FORT WAYNE, IN – BioPoly LLC announced that another US patent pertaining to the BioPoly®technology has issued. According to the Company, this patent protects the partial resurfacing implant designs and method of implantation. The patent is part of an extensive IP portfolio strategy that BioPoly LLC has employed to globally protect its unique orthopaedic material, manufacturing methods, and implant technology.
The proprietary BioPoly® material technology combines an orthopaedic polymer (i.e. ultra-high molecular weight polyethylene or UHMWPE) with an orthopaedic lubricating molecule, hyaluronic acid or HA. The combination of these materials results in a very unique and important orthopaedic material that is robust (due to the UHMWPE) enough to carry anatomical loads, yet self-lubricated (due to the HA) so that it is extremely biocompatible with cartilage tissues. BioPoly® orthopaedic implants, therefore, permit surgeons to replace only the damaged portion of joints (knee, patella, shoulder, etc.) as opposed to the entire joint. The BioPoly portfolio currently includes implants that partially resurface the joint, allowing patients to return to a pain-free lifestyle with normal activities very quickly.
BioPoly® products are CE marked and have been in use clinically since 2012. They are available in many countries throughout the world through our global distribution partner, OrthoD Group. BioPoly products have not yet been approved by the FDA for use in the US.
About BioPoly LLC
BioPoly LLC is an ISO 13485 certified orthopaedic implant manufacturer located in Fort Wayne, Indiana. The Company is developing, manufacturing and marketing products for use in sports medicine, orthopaedics, and spinal markets. Additional medical applications of the BioPoly® technology in cardiovascular and trauma markets are also being pursued.